An ability to readily determine an anticoagulant effect with an emerging class of direct, active
site, oral factor Xa inhibitors is viewed by the medical community as attractive and by some …

The introduction of oral direct anti-Xa anticoagulants apixaban and rivaroxaban has
significantly impacted the treatment and prevention of thromboembolic disease. Clinical …

Apixaban is a potent, highly selective, reversible, oral, direct factor Xa (fXa) inhibitor in
development for thrombosis prevention and treatment. The preclinical pharmacokinetic (PK) …

While laboratory monitoring is not required in patients treated with apixaban, a direct factor-
Xa inhibitor, assessment of its concentration is useful in some critical situations. However …

Abstract Apixaban (BMS-562247; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)
phenyl)-4, 5, 6, 7-tetrahydro-1 H-pyrazolo [3, 4-c] pyridine-3-carboxamide), a direct inhibitor …

Introduction Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the …

Apixaban is a potent, orally available, highly selective, and reversible factor Xa inhibitor, and
currently under development for prevention and treatment of thrombosis. The preclinical …

Background: Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late‐
stage clinical development for the prevention and treatment of thromboembolic diseases …

Apixaban is an oral, direct factor Xa inhibitor under development for secondary prevention in
acute coronary syndrome (ACS). Apixaban's effect on D-dimer and prothrombin fragment 1.2 …

For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …